Hepatoma-Targeted Radionuclide Immune Albumin Nanospheres: (131)I-antiAFPMcAb-GCV-BSA-NPs

Mei Lin; Junxing Huang; Dongsheng Zhang; Xingmao Jiang; Jia Zhang; Hong Yu; Yanhong Xiao; Yujuan Shi; Ting Guo

doi:10.1155/2016/9142198

Hepatoma-Targeted Radionuclide Immune Albumin Nanospheres: (131)I-antiAFPMcAb-GCV-BSA-NPs

Anal Cell Pathol (Amst). 2016:2016:9142198. doi: 10.1155/2016/9142198. Epub 2016 Feb 15.

Authors

Mei Lin¹, Junxing Huang², Dongsheng Zhang³, Xingmao Jiang⁴, Jia Zhang⁵, Hong Yu², Yanhong Xiao², Yujuan Shi², Ting Guo²

Affiliations

¹ Clinical Medical Institute, Taizhou People's Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, China; Medical School, Southeast University, Nanjing, Jiangsu 210009, China.
² Clinical Medical Institute, Taizhou People's Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, China.
³ Medical School, Southeast University, Nanjing, Jiangsu 210009, China; Jiangsu Key Laboratory for Biomaterials and Devices, Nanjing, Jiangsu 210009, China.
⁴ Key Laboratory of Advanced Catalytic Material and Technology, Changzhou University, Changzhou, Jiangsu 213000, China.
⁵ Medical School, Southeast University, Nanjing, Jiangsu 210009, China.

Abstract

An effective strategy has been developed for synthesis of radionuclide immune albumin nanospheres ((131)I-antiAFPMcAb-GCV-BSA-NPs). In vitro as well as in vivo targeting of (131)I-antiAFPMcAb-GCV-BSA-NPs to AFP-positive hepatoma was examined. In cultured HepG2 cells, the uptake and retention rates of (131)I-antiAFPMcAb-GCV-BSA-NPs were remarkably higher than those of (131)I alone. As well, the uptake rate and retention ratios of (131)I-antiAFPMcAb-GCV-BSA-NPs in AFP-positive HepG2 cells were also significantly higher than those in AFP-negative HEK293 cells. Compared to (131)I alone, (131)I-antiAFPMcAb-GCV-BSA-NPs were much more easily taken in and retained by hepatoma tissue, with a much higher T/NT. Due to good drug-loading, high encapsulation ratio, and highly selective affinity for AFP-positive tumors, the (131)I-antiAFPMcAb-GCV-BSA-NPs are promising for further effective radiation-gene therapy of hepatoma.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / immunology
Antibodies, Monoclonal / therapeutic use*
Carcinoma, Hepatocellular / genetics
Carcinoma, Hepatocellular / metabolism
Carcinoma, Hepatocellular / therapy*
Chemoradiotherapy / methods
Drug Delivery Systems / methods
Female
Ganciclovir / administration & dosage
Ganciclovir / therapeutic use*
Genetic Therapy / methods
HEK293 Cells
Hep G2 Cells
Humans
Iodine Radioisotopes / administration & dosage
Iodine Radioisotopes / pharmacokinetics
Iodine Radioisotopes / therapeutic use*
Liver Neoplasms / genetics
Liver Neoplasms / metabolism
Liver Neoplasms / therapy*
Mice, Inbred BALB C
Mice, Nude
Microscopy, Electron, Transmission
Nanospheres / administration & dosage
Nanospheres / chemistry
Nanospheres / ultrastructure
Serum Albumin, Bovine / chemistry
Tissue Distribution
Xenograft Model Antitumor Assays
alpha-Fetoproteins / genetics
alpha-Fetoproteins / immunology

Substances

Antibodies, Monoclonal
Iodine Radioisotopes
alpha-Fetoproteins
Serum Albumin, Bovine
Ganciclovir